Ex-Immunomedics Brass Must Face Del. Suit Over $250M Deal
By Rose Krebs ( November 13, 2019, 7:11 PM EST) -- A Delaware vice chancellor on Wednesday said enough evidence has been shown to infer four former directors of biotechnology firm Immunomedics Inc. possibly acted in bad faith when they approved a $250 million deal — which has since been unwound — to license the company's main drug candidate to a third party in 2017....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.